Allergen-specific immunotherapy (AIT) is the only internationally recognized method for treating allergic diseases and can change the natural course of the disease. According to the duration of the dose accumulation phase, it is divided into conventional and accelerated AIT, and accelerated AIT is further divided into cluster, shock and super shock AIT. Ultrarush AIT (UR AIT) allows patients to receive increasing doses of allergen extracts multiple times every 15 to 60 minutes, quickly reaching the maintenance dose, and shortening the dose accumulation phase to 1 to 2 days. The author synthesized the relevant literature on accelerated AIT at home and abroad, and summarized the UR AIT research conducted in allergic diseases such as allergic rhinitis, allergic asthma, and atopic dermatitis. It was found that despite the different allergen preparations and diseases treated, UR AIT showed good safety and effectiveness. However, current UR AIT research is mainly retrospective and observational. Due to the heterogeneity of allergen preparations, time courses, and subject populations, it is difficult to make consistent comparisons of research results. In the future, multi-center, large-sample studies are needed. Randomized controlled trials were conducted to further explore its effectiveness and safety.